Alzamend Neuro Inc (ALZN)

[Golden Cross]

$ALZN Insider buys 145,000 more shares!

[Roozy]

Maybe 2 3 4 now that’s funny

[Roozy]

Check the trade sizes! “1”
That’s funny ??

[WiseYoda]

Dropping hard....hopefully we see some recovery this week.

[WiseYoda]

Brutal...

[Roozy]

Heavy manipulation in evidence

[WiseYoda]

Come on you POS....disseminate some damn news!

[WiseYoda]

That was a good read...shes going to make her way north back over $3. Its coming.

[PennyStockTrader2]

Wrote an unimaginable number of call options on this last push up, unfortunately some at low premiums and far out expirations, but they're all covered (or i wouldnt have written them). But also have a decent number expiring in Nov and Dec which will open things up for writing future options. Now I knew very well that my premiums were crappy when I started writing in the last couple weeks when the stock was hovering in the low 2s, but at the same time I really wanted the cash for other investments, but in hindsight I should have bitten the bullet and waited for the rally which, with Todds stocks are inevitable, where the premiums spiked nicely, lesson learnt.

On the puts options side, the 2.50 put for any of expirations have decent premiums, for starters I wrote 20 Nov 2.50 puts for between .45 and .50, which is pretty darned good, while the margin required is equivalent to the strike price, in other words the 2.50 put requires $250 margin (regardless of expire date) basically assuming the stock will go to zero which is unfair but still, for example looking at the November option, getting $45 with a requirement of $250 bucks is 18% profit in 2 weeks, with fairly low risk (it'd have to go to $2.05 where you would at least break even) can't complain about that at all. What we need is for the exchange to provide options at strikes at every 50 cents in order to capitalize on a long term put/call options trading plan, as I have done very nicely with DPW (aka Ault Holdings) for almost a year now. With the insane options volume on Friday, and decent volume even before that, I expect we'll see those new strikes being offered in the near future, it didnt take that long for DPW to get those 50 cent ladder options as well after options trading started for it. With a variety of strikes, you can write options at various prices and various expirations that should be profitable over time. The key is having the underlying stock to allow for it, and at $2.50/share, you can load up nicely and put such a strategy into action.

A full blown strategy of both puts and covered calls could pull in lets say .85/option pair (.45 5.0 call + .40 2.50 put) and if yu did that 3 months in a row for the front month contract, you could literally pay for the stock itself, all assuming the options go out worthless with the stock finishing in the very wide range of $2.50 - $5.00. I plan on doing exactly that as soon as my cash position gets strong after one of my other pennies runs to the sky. In the case the stock just runs thru the roof on its own, you have still at least doubled your money on the upside with addl money made as the puts go out worthless.

[WiseYoda]

Yes!

[NewGuy001]

Lots of Red today. Hopefully it filps by end of day!

[beambe]

https://investorplace.com/2021/11/alzn-stock-why-is-little-known-alzamend-neuro-gaining-today/

[TheFinalCD]

100k shares @ .0004 = $40



100k x $3= $300,00

$40 to $300,00


craZy right

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=166661183

[Golden Cross]

$ALZN Univest $15 PT--->>>>

[zagdad]

The first initiation and coverage but an old release....look to the new one too. Not sure of the date....maybe the poster does?

[Golden Cross]

$ALZN - Ascendiant Capital analyst Edward Woo Initiates Coverage on Alzamend Neuro Inc With a Buy Rating and a Price Target of $8.00.

[Monksdream]

The DD board has been discussing it. They're not sure what to make of it, either.

[WiseYoda]

Its great momentum going into the weekend....makes it more likely that it will carry over to Monday. Lots eyes will be here PM Monday morning.

[TheFinalCD]

show it!!!

[TheFinalCD]

3.03 x 3.05 lookin better a/h

maybe because its a friday ah?


dunno, we shall see monday

[WiseYoda]

Indeed it is!

$ALZN

[Golden Cross]

Starting off good at least WY.... $ALZN

[WiseYoda]

Exactly what I was thinking.

[Golden Cross]

Bet we see some nice AH's and PM Monday on this puppy

[WiseYoda]

Indeed!

[TheFinalCD]

what a freakin struggle


WOW~!

[WiseYoda]

13k shares @ 2.92 looking good....time for power hour!

[Golden Cross]

132 MIlly Volume so far!

[beambe]

https://alzamend.com/

[beambe]

Alzamend Neuro Inc (ALZN)
2.88 ? 0.59 (25.76%)
Volume: 127,451,046 @11/05/21 2:10:18

[beambe]

BUY
Initiation Report November 5, 2021
Alzamend Neuro
NASDAQ: ALZN: $2.29 Target: $15.00
James Jang
Director of Research
[e-mail]
212.343.8888
From the Earth to the Brain, Lithium Puts the
Li in Life: Initiating Coverage of Alzamend
(ALZN)

Investment recommendation
Investment Highlights
• AL001 use for Alzheimer’s Disease is a way to shorten the timeline for
the other indications of depression, PTSD, and bipolar disorder where
we believe there is a better market for lithium. The FDA has programs
in place for breakthrough therapies and fast track that allow
experimental drugs to get through the approval process faster.
Alzamend has the potential to file for these programs with their AL001
drug for Alzheimer’s, which would allow for quicker data gathering that
can then be used for the other indications. Since AL001 will be the
same formulation for each indication, safety and tolerability can be
skipped for the other indications and trials can smaller and quicker
which can reduce time to approval.
• Reformulation of an approved therapy allows for easy acceptance with
safer profile. Lithium Carbonate has been an approved therapy for
many years for bipolar disorder and off-label use for depression. While
it is an approved therapy, there are still many risks associated with this
treatment; with high levels of lithium causing liver and kidney damage.
Alzamend’s new formulation helps to limit these issues while extending
the therapeutic window (reduce dosage), while maintaining a high level
of efficacy. Since Lithium is an approved therapy, we expect AL001 to
have a shorter pathway through clinical trails. This should lead to a
reduction in the time to approval, lower costs, and the potential for
quicker revenue generation.
Based on our discounted cash flow (DCF) methodology, we value ALZN at
$15 per share which is based on about a 1.0x multiple to our DCF derived
price of $14.81. Currently, we are conservatively omitting AL001 and AL002
indications for Alzheimer’s Disease from our estimates at this time. While we
believe ALZN’s differentiated approach to Alzheimer’s Disease could serve as
a major catalyst, at this time we view the AL001 and AL002 programs for
Alzheimer’s Disease as a free call option at current valuation levels. Therefore,
we initiate coverage of ALZN with a BUY rating and $15 price target.
REVENUE (000s)
EBITDA (000s)
Consumer Products - Nutraceuticals
EPS
We are initiating coverage of Alzamend Neuro (ALZN) with a BUY rating and
$15 price target. We believe ALZN could unlock a quicker pathway to
revenue generation by utilizing its patented AL001 (LiProSal) ionic cocrystal
to treat a host of psychiatric disor

[WiseYoda]

I was impatient and jumped in at 2.92. Such an amateur move but oh well. This one is moving more north.

[TheFinalCD]

i missed the dip to 2.68

grrrr

[WiseYoda]

13k @ 2.92 lets go!

[beambe]

Buy recommendation target price $ 15

[Golden Cross]

Alzamend Neuro shares soar 26% on large shareholder buy
https://ih.advfn.com/stock-market/NASDAQ/alzamend-neuro-ALZN/stock-news/86480124/alzamend-neuro-shares-soar-26-on-large-shareholde

[TheFinalCD]

https://ih.advfn.com/stock-market/NASDAQ/alzamend-neuro-ALZN/stock-news/86480124/alzamend-neuro-shares-soar-26-on-large-shareholde



is that a joke 100k shares @ .0004??

https://ih.advfn.com/stock-market/NASDAQ/alzamend-neuro-ALZN/stock-news/86469970/statement-of-changes-in-beneficial-ownership-4


Stock Options (Right to Buy) $0.0004 11/3/2021 M 100000 (5) 4/29/2026

[TheFinalCD]

whats that?

[beambe]

BUY
Initiation Report November 5, 2021
Alzamend Neuro
NASDAQ: ALZN: $2.29 Target: $15.00
James Jang
Director of Research
[e-mail]
212.343.8888
From the Earth to the Brain, Lithium Puts the
Li in Life: Initiating Coverage of Alzamend
(ALZN)

Investment recommendation
Investment Highlights
• AL001 use for Alzheimer’s Disease is a way to shorten the timeline for
the other indications of depression, PTSD, and bipolar disorder where
we believe there is a better market for lithium. The FDA has programs
in place for breakthrough therapies and fast track that allow
experimental drugs to get through the approval process faster.
Alzamend has the potential to file for these programs with their AL001
drug for Alzheimer’s, which would allow for quicker data gathering that
can then be used for the other indications. Since AL001 will be the
same formulation for each indication, safety and tolerability can be
skipped for the other indications and trials can smaller and quicker
which can reduce time to approval.
• Reformulation of an approved therapy allows for easy acceptance with
safer profile. Lithium Carbonate has been an approved therapy for
many years for bipolar disorder and off-label use for depression. While
it is an approved therapy, there are still many risks associated with this
treatment; with high levels of lithium causing liver and kidney damage.
Alzamend’s new formulation helps to limit these issues while extending
the therapeutic window (reduce dosage), while maintaining a high level
of efficacy. Since Lithium is an approved therapy, we expect AL001 to
have a shorter pathway through clinical trails. This should lead to a
reduction in the time to approval, lower costs, and the potential for
quicker revenue generation.
Based on our discounted cash flow (DCF) methodology, we value ALZN at
$15 per share which is based on about a 1.0x multiple to our DCF derived
price of $14.81. Currently, we are conservatively omitting AL001 and AL002
indications for Alzheimer’s Disease from our estimates at this time. While we
believe ALZN’s differentiated approach to Alzheimer’s Disease could serve as
a major catalyst, at this time we view the AL001 and AL002 programs for
Alzheimer’s Disease as a free call option at current valuation levels. Therefore,
we initiate coverage of ALZN with a BUY rating and $15 price target.
REVENUE (000s)
EBITDA (000s)
Consumer Products - Nutraceuticals
EPS
We are initiating coverage of Alzamend Neuro (ALZN) with a BUY rating and
$15 price target. We believe ALZN could unlock a quicker pathway to
revenue generation by utilizing its patented AL001 (LiProSal) ionic cocrystal
to treat a host of psychiatric disorders.
The recommendations and opinions expressed in this research report accurately reflect the Investment Analyst’s personal, independent, and
objective views about any and all the Designated Investments and Relevant Issuers discussed herein. For important information, please see
the Import Disclosures section in the appendix of this document.


SHARE PRICE PERFORMANCE
Valuation
Cash (000)
GAAP EPS
BIOTECHNOLOGY F2021 F2022E F2023E
1Q ($0.03)A ($0.03)E
2Q ($0.02)E ($0.03)E
3Q ($0.02)E ($0.03)E
4Q ($0.02)E ($0.02)E
FY ($0.07)A ($0.10)E ($0.10)EF2021 F2022E F2023E
1Q $15,618A $8,461E
2Q $14,880E $4,938E
3Q $13,533E $13,393E
4Q $12,032E $11,614E
FY $1,929A $12,032E $11,614E -
10,000,000
20,000,000
30,000,000
40,000,000
50,000,000
60,000,000
$2.00
$4.00
$6.00
$8.00
$10.00
$12.00
$14.00
6/15/2021 7/15/2021 8/15/2021 9/15/2021 10/15/2021
Volume (RHS) Price (LHS)Comp a ny St a t ist ics
Closing Price 11/4/2021 $2.29
52-week Range $2.04 - $33.55
Market Cap (M): $198.97
Avg. Daily Volume: 2,119,516
Debt (M): 0.34
Risk Profile: High
Fiscal Year End: April

[beambe]

file:///C:/Users/BERNHA~1/AppData/Local/Temp/Univest_Securities_-_Alzamend_Neuro_Intiation_2021-1.pdf

[TheFinalCD]

102M volume on 84m o/s 44 float https://finviz.com/quote.ashx?t=ALZN


this chit has to be illegal


its freakin sad that they can manipulate, wash trade, naked short the hell out of anything they want, not much we can do about it, ecxcept shake our heads and try to make some money off the BS

[europtiger]

Thx for heads up… bought 3

[TheFinalCD]

cRAZY lEGS


ALZN

[Avidfisher]

I bought 15k shares last few days per my confidence, per these recent preliminary results. Got 5k of it today @ $2.18 average.

[PennyStockTrader2]

this is languishing bad, and you cant even write call options against it with such crappy premiums. Look even right now the 2.50 call for december is fetching like 30 cents, big-woof, not worth it. Nobody believes that the price will rise, which is just when it can. That said I picked up 1000 shares just in case it does.

[zagdad]

Ascendiant Capital Markets initiates coverage of ALZN with a buy and an initial projection of $8, Serious write up and my initial read liked what I saw. Not a paid promotion but a serious coverage per the disclosures IMHO.

It follows on the great news from the FDA yesterday on their trials.

https://ascendiant.sharefile.com/share/view/1b052a7017b340be

[PennyStockTrader2]

took advantage of the spike today to sell some shares and write some Oct 5.0 calls which should go out worthless. I would buy on pullback to maybe the 2.60 range.

[europtiger]

I buy the volume breakout 3,05 stop 2,65

[europtiger]

Bought 3,05

[Roadtojourney]

And down it goes pump and dump pos?? Imo